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Intrudoction
 Marine organisms comprise over a half millon species and inhabit very 
unusual circumstances as compared with terrestrial organisms. Some orga-
nisms, such as marine algae, marine sponges, tunicates, nudibranchs, and 
bryozoans, lack any physical defence means in  thier structures to avoid 
the menace of predators and the infection of pathogenic microorganisms. 
In order to keep alive and adapt in these severe environment, marine orga-
nisms seem to develop suitable bio-defence systems with characteristic me-
tabolisms which are significantly different from those known in terrestri-
al organisms. 
  In this relation, the chemical metabolites of marine organisms have been 
paid much attention in recent years and an increasing number of marine na-
tural products have been discovered. Those substances are not only diverse 
in their chemical structures, but also shown to exhibit varieties of bio-
logial activities, e.g. growth inhibitions against pathogenic microorga-
nisms, physiological functions (pheromone, allelochemic and synomene), 
pharmacological actions, cytotoxicities and anti-cancer activities, and 
toxici ties. 
  In this mean, the effort to discover new anti-cancer substances from ma-
rine organisms has been also undertaken. The resulting several interest 
biopolymers, for example the antineoplastic glycoproteins such as sphyrna-
stains from the hummerhead shark (Sphyrna lemini), stronglostains from the 
sea urchin (Stronglocentrolus drobachiensis), aplysianins from the sea 
hare (Aplysia kurodai) and dolabellanins from another sea hare (Dolabella  
auricularia) have been isolated recently. On the other hand, many novel. 
antineoplastic compounds having usual molecular weight (e.g. macrolides, 
peptides,alkaloids, terpenoids and others) have been isolated from many 
marine organisms. 
  In this article, the important chemically clarified biopolymers, having 
strongly cytostatic and potent antineoplastic activities, from marine or-
ganisms were reviewed.
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            1. Example of The Biopolymer Screening 
  Recently, Sasaki and  Endo" have discovered the important antineoplastic 
polymer fractions from the water extracts of 25 marine organisms, in which 
the popular marine animals as Japanese foods, e.g. Awabi (Haliotis discus  
hannai), Sazae (Butillus cornutus), Hotategai (Aequipecten irradians), 
etc.are including. 
  The molecular weights and antineoplastic (in vivo) activities against 
sarcoma-180 of fractionated polymers were summarized in Table 1. Each po-
lymer fraction was yielded by usual fractionation with Sephadex seies. 
  The in vivo activity against Sarcoma-180 (mice) for polymer fractions 
was obtained by the systematic imjection (i.p. 400mg/Kg/dose) to ICR mice 
(female). From the data in Table 1, it was found that many marine organis-
ms produced the orginal antineoplastic polymers. In them, the polymers 
from Haliotis diversicolor aquatilis (Tokobushi), Butillus cornutus (Sazae 
), Placopecten magellanicus (Hotategai), Mercenaria mercenaria (Honbinosu-
gai), Crassostrea virginica (Americagaki) and Ecteinascidia turbinata ( 
Guntaiboya) showed the remarkale antineoplastic activities over 80% effect 
, respectively. 
  However, unfortunately, the exteuded purication and identification of 
these biopolymer fractions are not completed at this time.
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a) Antitumor in vivo Activity against Sarcoma-180 (abdominal dropsy 
cell) was estimated by the followed formula. 
      Activity (%)=(A-B)/Ax100 
A: Avarage of tumor weight on control 
B: Avarage of tumor weihgt on treatment 
In the experiment, ICR mice (female, ca. 23g weight) was used . 
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 2  . Sphyrnastatins and Strongylostatins 
   In 1977, Pettit and Ode reported that two antineoplastic glycoproteins, designated 
 sphyrnastatin 1 and sphyrnastatin 2, were isolated from the water extract of blood and 
 body fluids of the hurnmerhead shark Sphyrna lemini by chromatography on 
 macroreticular resin followed by gel permeation chromatography. 
    Sphyrnastatins 1 and 2 were glycoproteins of 22% and 26% carbohydrate, 
respectively, with apparent molecular weights of at least 40x106 Amino acid analyses 
 indicated a minimum protein segment of 274 amino acid units for sphyrnastatin 1 and 380 
    amino acid units for sphyrnastatin 2. Upon biological evaluation, both compounds 
    produced a 30-40%(at 11-13 mg/kg dose) life extension in mice inoculated with P-388 
    murine lymphocytic leukemia. 2 
      In 1979, Pettit and co-workers reported that a new glycoprotein antineoplastic agent 
    designated strongylostatin 1 was isolated from the water extract of the well-known green 
    sea urchin Stronglocentrollcs drobaclziensis (Muller) of the Strongylocentrotideae family. 
    A series of gel permeation chromatography was used for separation. The apparent 
    molecular weight of this compound appeared to be over 40x 106. The results of amino 
    acid analyses suggested a minimum protein segment of 546 amino acid units. 
    Strongylostatin 1 (approximately 1.6% yield based on the aqueous extract) was found to 
    produce 35-53% life extension in the P388 murine lymphocytic leukemia system. 3' 
      In 1981, Pettit and co-workers described that the same green sea urchin was found to 
    contain a second protein anticancer constitutent designated strongylostatin 2. It was 
    found to be a glycoprotein with a unit/subunit molecular weight of at least 65,000. An 
    amino acid analysis showed Gly to be most prominent, and the carbohydrate portion was 
    estimated to represent 22% of the glycoprotein. Treatment of the murine P388 
lyrnphocytic leukemia with strongylostatin 2 resulted in 39-42% life extension at a dose 
    of 4.5mg/kg. "
3 , Aplysianins 
 Recently, Kamiya and co-workers reported that three antitumor factors, aplysianins A, 
E and P, inducing tumor lysis were isolated from the sea hare Aplysia kurodai. 
Aplysianin E was purified to apparent homogeneity from the supernatant of a homogenate 
of eggs of Aplysia kurodai. Purified aplysianin E was a 250kDa glycoprotein containing 
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three different subunits. This factor was half-maximally active at 2-114 ng  protein/ml 
and lysed all the tumor cells tested but did not lyse normal white or red blood cells. 
Aplysianin E was labile on treatments with heat, low pH, urea, guanidine, sodium lauryl 
sulfate, and periodatc, but not with proteases or organic solvents. Aplysianin E 
completely inhibited the syntheses of DNA, RNA, and protein by tumor cells within 2 h 
and caused their complete cytolysis within 15 h. Tumor lysis by aplysianin E was 
inhibited by N-acetylneuraminic acid, suggesting that recognition of the sugar moiety is a 
key step in cytolysis induced by aplysianin E. Aplysianin E also prolonged the survival 
of mice bearing syngeneic MM46 ascites or solid tumors. 5) 6 )
  The cytolytic activity against various target cells was examined as 
shown in Table 2. All the murine and human tumor cells tested were lysed 
by purified aplysianin E in the concentration range of 2-114 ng protein/ml 
. In contrast, normal spleen cells and erythrocytes were resistant to this 
cytolytic factor. These results indicate that tumor cells are relatively 
susceptible to aplysianin E.
6)8)
Table 2 Target cell specificity of aplysianin E
Target cells






MM46 (mammary carcinoma) 







PC-6 (lung adcnocarcinoma) 
PC-7 (lung adenocarcinoma) 
PC-9 (lung adenocarcinoma) 
Spleen cells 
Erythrocytes
   2 
  35 
   2 
  30
  114 
   9 
   13
  30 
  30 
  30 
  60 
>1600 
>1600
  • Target cells were Incubated with aplysianin E for 18 h . EDso, concentration 
for 50% lysis of target cells.
 Table 3 shows 
effect against 
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 that aplysianin 
the MM 46 tumor. 
a lethal dose fo
E as well as mitomycin 
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16.2 ± 0.8` 
  >45 
17.0 ± 0.0 







18.8 ± 1.6 
15.2 ± 2.5 
•• 55 
18.0 ± 1.4 
  19
   Murine MM46 tumor cells were pretreated with mitomycin C or aplysianin 
E in vitro at 37.0 for 60 min. Then the cells (5 x 10' cells/mouse) were inoculated 
i.p. into C311/11e mice. Data are representative of two similar experiments. 6 Fresh MM46 tumor cells (5 x 10' cells/mouse) were inoculated i.p. into 
surviving mice 50 days after neutralization. 
Mean ± SD. 
g One unit equals 8.2 pg of protein.
  Aplysianin A was isolated from the albumen gland of Aplysia kurodai.. The 
aplysianin A obtained showed similar physiological activity to that of aplysianin E, an 
active factor in eggs. It showed a 50% inhibition of 13. subtilis growth at a concentration 
of 411g protein/ml. The concentration required for 50% lysis of murinc MM46 tumor cells 
was as low as 14ng protein/ml. Physicochemical properties were, on the other hand, 
quite different from those of aplysianin E. Aplysianin A, which has a molecular weight 
of approximately 320,000 and contains four Mr 85,000 subunits, is larger than aplysianin 
E. However, these two factors have a common antigen and a similar amino acid 
composition, suggesting that aplysianin A is a precursor of aplysianin E. 7 ) 
   Aplysianin P was purified from the purple fluid of Aplysia kurodai. purified 
aplysianin P was a single polypeptide of m.w. 60,000. This factor was half-maximally 
active at 3-25 ng protein/ml and lysed all the tumor cells tested but did not lyse normal 
WBC or RBC. Aplysianin P was labile on treatments with heat, low pH, urea, and 
periodate, but not with Pronase. The factor completely inhibited the syntheses of DNA, 
RNA, and protein by tumor cells within 2 h and caused their complete cytolysis within 18 
h. Tumor lysis by aplysianin P was also inhibited by N-acetylneuraminic acid, 
suggesting that recognition of the sugar moiety is a key step in the cytolysis induced by 
aplysianin P. The factor also prolonged the survival of mice bearing syngeneic MM46 
ascites. It did not resemble previously isolated antineoplastic glycoproteins from the 
eggs(aplysianin E) or albumen gland (aplysianin A) of A. kurodai in terms of molecular 
size, antigenicity, or amino acid composition. 8' 9 )
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 The cytolytic activity againgst various target cells was  examined, as 
shown in Table 4 all the murine and human tumor cells tested were lysed 
purified aplysianin P in the concentration range of 3-25 ng protein/ml. 
contrast, normal spleen cells and erythrocytes were resistant to this cy 
tolytic factor. These results indicate that tumor cells are relatively 
susceptible to aplysianin P.
by 
In
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1-Iunian 
  K-562 (leukemia) 
Raji (leukemia) 
  Molt-3 (leukemia) 
  PC-6 (lung adenocarcinoma) 
PC-7 (lung adenocarcinoma) 
  PC-9 (lung adenocarcinoma) 
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   Target cells were Incubated wtih aplysianin P for 18 Ii. ED,e, concentration 
for 50% lysis of target cells.
4. Dolabellanins
 The Indian and the Pacific Ocean sea hare, Dolabella auricularia, is a 
large shell-less opisthobranch mollusk which is found intertidally feeding 
on brown algae. Dolabella auricularia contain cytotoxic and/or antineo-
plastic subustances such as dolastatins, as shown in the section of pep-
tides. These substances are low molecular weight compounds. Recently, Kam 
iya and co-workers found high moleular weight compounds with antineoplas-
tic and antibacterial activities in the body fluid, albumen gland and 
purple fluid of Dolabella auricularia. These active substances of Dolabel-
la auricularia were also isolated as glycoproteins, which differed from 
aplysianins in Aplysia kurodai.le)-13) 
  An antineoplastic factor, dolabelanin C, including tumor lysis activitiy 
was purified to apparent homogeneity from the body fluid of the sea hare 
Dolabella auricularia. Purified dolabellanin C is a glycoprotein of 215 
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kDa cotainig 3 subunits of 70 kDa. The amino acid sequence of the amino 
terminal region was also determined. This factor was active even at 0.38ng 
 protein/ml, but did not lyse normal white or red blood cells.1) 
Dolabellanin A was purified to apparent homogeneity from the albumen 
gland of the sea hare Dolabella auricularia. Dolabellanin A was a glyco-
protein of 250 kDa cotaining 4 subunits. The amino acid composition and 
the N-terminal amino acid sequence of the factor were determined. By dola-
bellanin A, all the murine and human tumor cells tested were lysed at the 
concentration range of 1-18 ng protein/ml (Table 5). The in vivo antitumor 
activity of dolabellanin A was tested by incubating mixtures of tumor 
cells and dolabellanin A in vitro and then injecting them intraperitoneal-
ly into mice. (Table 6). Mitomycin C was used as a positive control. Dola-
bellanin A had protective effect against the MM46 tumor (P>0.001) and also 
some animals survived after injection of 4 ng/mouse daily for 6 days 
(see Table 6). 11) 12)
11)






MM46 (mammary carcinoma) 
MM48 (mammary carcinoma) 
M11134  (hepatoma) 
Macrophages 
Lymphocytes 
Rcd blood cells 
A549 (lung carcinoma) 
LS 174T (colon carcinoma) 
T24 (bladder carcinoma) 
WiDr (colon carcinomn) 
TIG-I (fetal lung) 
I M R-90 (fetal lung) 
W1-38 (lung diploid) 
Red blood cells
   18 
   6 
    2 
  525
I x 10' 
>2x 10' 
     1.2 
     3.4 
      1.2 
     0.9
   62 
   68 
  120 
>2x 10'
 a) Target cells were incubated with dolabcllunin A for I R h. 
for 5O' lysis of target cells.
ED«. concentration
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                                                       12) 









Expt. I (Neutralization)" 
 Saline
 Mitomycin C 10 pg 
 Dolabellanin A 0.2 pg 
Dolabellanin A 2 pg 
 Dolabellanin A 20 pg 
Expt. II (i.p.injection)") 
 Saline0.2 ml x 6 
Mitomycin C 10 pg x 6 
Dolabcllanin A 0.8 pg x 6 










 16.8 ± 0.8 
> 50 





17.3 ± 1.4 
20.3±4.2 p <0.001
a) /Amine MM46 tumor cells were treated with mitomycin C or dulabellarrin A in 
vitro. at 37"C For 31) min. Thcn the cclls (5 x 1U1 cclls/mouse) were injected i.p. into 
('311/l le mice. h) C311/Ile mice received ;iscitic MM46 cclls i.p. on day 0 and were 
treated i.p. with saline. nsitontycin C or dolabellanin A daily for 6d from day 0.
  Third cytolytic factor, dolabellanin P, was purified to apparent homogeneity from the 
purple fluid of Dolabella auricularia. Purified dolabellanin P is a single polypeptide of 
60 kDa. Examination of the amino acid composition of dolabellanin P revealed that it 
contained a relatively large amount of .Asx and Gix. The sequence of the amino terminal 
region of dolabellatnin P was shown: 
Val-( )-Arg-Glu-Asp-Gln-Lys-Trp-Lys-Leu-Ser-Phe-Asp-Lys-Glu-------- 
    This factor nonspecifically lysed all the cell tested at 50-200ng protein/ml. 
Dolabellanin P caused completed cytolysis within 2h. l 3) , as shown in Table 7.
13)
Table 7 Target Cell Specificity of Dolabcllanin P




MM46 (mammary adenocarcinoma) 
MM48 (mammary adcnocarcinoma) 
MI1134 (lung adcnocarcinoma) 
A 549 (lung adenocarcinoma) 
1' 24 (urinary bladder carcinoma) 











 a) Target cells were incubated with dolabellanin P for 18 h. EDso: 
giving 50% lysis of target cclls.
concentration
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5  , Halitoxin 
 Baslow et al. reported that the aqueous extracts of the sponge Haliclona viridis was 
14) 
toxic for mice. Ten years later (1978), from several species of the same genus 
Haliclona, a cytotoxic metabolite called halitoxin (1) was isolated by Schmitz and co-
workers. The structure proposed for halitoxin was a polymer consisting of various 
combination of different pyridinium units of two general structural types, as shown in 
Chart.12) Halitoxin was hemolytic and toxic to fish and mice. The cytotoxity of 
fractionated halitoxin R (m.w. 500-1000) was reported as ED50 2.8 µg/m1 in KB cell 


















 Mucus secreted from the integument of the marine heteronemertine Cerebratulus lacteus 
(Leidy) contains two major types of polypeptide neurotoxin. The A toxins (11,000 
daltons) which are lethaI to a variety of animal species including mammals. The B toxins 
(6,000 daltons) which appear to be selectively toxic for crustaceans. BOth types of toxin 
were readily obtained from live worms by stimulation and collection of mucus with 1% 
acetic acid followed by batch adsorption of the basic polypeptide fraction on CM-
cellulose. 1 6 ) 
  A toxins were homogeneous by gel electrophoreses and amino acid composition 
analyses, and by NH2 -terminal and COOH-terminal partial sequence analyses. 
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 As shown in Chart 2, each of three A toxins(2) consists of a single basic polypeptide 
chain of 93 to 99 residues, cross-linked by three or four disulfide bonds, lacking 
reducing sugar and cyteinyl residues. The three A toxins rapidly lysed human red cells 
































 ?  . Antineoplastic Polymers from Marine Bacteria 
    An active polysaccharide, named marinactan was obtained by Umezawa and co-
workers by a screening of antitumor activity against sarcoma 180 solid tumor in mice 
from the marine bacterium Flavobacterium uliginosum. Marinactan is a novel 
heteroglycan consisting of glucose, mannose and fructose in a ratio of approximately 
7:2:1. Marinactan, 10-50mg/kg per day for 10 days i.p., produced 70-90% inhibition of 
the growth of solid sarcoma 180. Complete regression of the tumor was observed in 
some treated mice. Its administrations before and after tumor transplantation showed 
almost the same inhibitory effect. Marinactan prolonged markedly the survival period of 
mice bearing ascites sarcoma 180.18' 
 Antirumor activity of the marine bacterium, Vibrio anguillarum P-B-1 against Ehrlich 
carcinoma cells in ddY mice, was investigated by Shimizu and co-workers. The aqueous 
layer obtained by the hot phenol-water procedure exhibited more antitumor activity than 
did the middle layer or the phenol layer. This finding indicated that lipopolysaccharide 
(LPS) derived from V. anguillarum exhibited significant antitumor activity. In fact, mice 
injected with LPS obtained by ultracentrifugation and treatment with RNase had a longer 
mean survival period than the control mice. V. anguillarum LPS also inhibited the 
growth of syngeneicfibrosarcoma induced by 3-methylcholanthrene in C57BL/6 mice.9' 
  By Creech and Breuninger, the antitumor properties of polysaccharide fractions, 
obtained by high speed centrifugation of aqueous extracts of the cells of Serratia
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 marcescens followed by phenol extraction and trypsin digestion , were investigated. The 
polysaccharide fractions were highly effective in causing complete regression of well 
established solid sarcoma 37 in Swiss mice . The products derived primarily from the cell 
wall were more potent than the polysaccharides of extracellula
r and cytoplasnic 
origins.2e'
8. Mieellaneous 
Boiled Scallop Extract.2 ' ) Sasaki and co-workers reported that a fraction from boiled 
scallop extract modified by a sonication procedure exhibited marked antitumor activity 
when it was injected intradermally into either ICR or C3I-I/I-Ie mice that had been given 
SC implants of sarcoma 180 and Ehrlich carcinoma. However, this fraction was almost 
ineffective against L1210 cells. In a smaller dose (100 mg/kg) in in vivo sarcoma 180 
test, this fraction was still effective. It had an inhibition ratio of 74.2% and caused 
complete tumor regression in 2 of 5 mice. The inhibition ratio observed with Ehrlich 
carcinoma was 73.5%. From the result of a further fractionation and purification, this 
fraction was found to contain two active principles -one was probably a heat-stable 
protein (mol. wt., —21,000 daltons) and the other, a heat-unstable peptidoglycan (mol. 
wt., — 100,000 daltons). 
   Mercenaria extract. 2 2' In 1964, Schmeer reported that a polymeric fraction, which 
was obtained from the water extract of Mercenaria mercenaria by partial purification with 
sephadex G-25, inhibited both sarcoma 180 and Krebs 2 carcinoma in Swiss albino 
mice. Unfortunately, further investigation has not been done. 
   Marine Animal Lecti,i? 3' By Kamiya and co-workers, several lectins from marine 
animals, such as Balanus roseus hemagglutinin, B. balanoides hemagglutinin, 
Tetraclita squamosa japonica hemagglutinin and Aplysia kurodai agglutinin, were tested 
for induction of tumor lysis mediated by macrophages. Among them, B. roseus and B. 
balanoides lectins agglutinated several murineitumor cells and induced binding of 
 macrophages to tumor cells. Binding of these cells was inhibited by galacturonic acid, 
 suggesting that carbohydrate moieties on the cell membrane of the two types of cells are 
 recognized by these lectins. B.roseus lectin was also effective in vivo.
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